New data from Alemtuzumab phase 2 MS trial released
Posted: Sun Apr 10, 2011 3:12 am
Genzyme, a subsidiary of sanofi-aventis Group announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.
Included among the additional Phase 2 trial safety and efficacy data at AAN will be presentations on the clinically-active disease status of patients through five-years of patient follow-up as well as data describing a measure of vision improvement.
"We are excited to present new alemtuzumab data at AAN that further reflectsalemtuzumab's potential as an MS treatment," said Michael Panzara, Genzyme Group Vice President and Therapeutic Area Head for Multiple Sclerosis and Immune Diseases. "We look forward to the availability of Phase 3 results in the middle of this year.".. Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307